Petta, S., Cabibbo, G., Barbara, M., Attardo, S., Bucci, L., Farinati, F., et al. (2017) Hepatocellular Carcinoma Recurrence in Patients with Curative Resection or Ablation: Impact of HCV Eradication Does Not Depend on the Use of Interferon. Alimentary Pharmacology & Therapeutics, 45, 160-168.
https://doi.org/10.1111/apt.13821

has been cited by the following article:

• TITLE: Rapid Development of Hepatocellular Carcinoma after Eradication of Hepatitis C Virus with Directly Acting Antiviral Treatment

  AUTHORS: Fakhar Ali Qazi Arisar, Saeed Hamid

  KEYWORDS: Direct Acting Antivirals, Hepatitis C, Hepatocellular Carcinoma, Hepatoma

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.8 No.9, September 19, 2018

  ABSTRACT: Hepatitis C is a major risk factor for the development of hepatocellular carcinoma (HCC), arising typically on a background of liver cirrhosis. Treatment of hepatitis C has been revolutionized by the addition of oral direct-acting antivirals (DAAs) with sustained virological response (SVR) rates above 90%. There is a recent concern under debate about the increased risk of early HCC recurrence in patients with chronic hepatitis C who were treated with direct-acting antivirals. Nonetheless, these reports mostly focused on patients who were cirrhotic and were already treated for HCC. We report 4 cases of treatment naive, chronic hepatitis C patients who were treated with DAAs and rapidly developed infiltrative HCC despite achieving SVR. Moreover, in our scenario, one of the patients appeared clinically non-cirrhotic until he developed HCC.